These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32976855)

  • 41. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages.
    Abe M; Matsuda M; Kobayashi H; Miyata Y; Nakayama Y; Komuro R; Fukuhara A; Shimomura I
    Arterioscler Thromb Vasc Biol; 2008 May; 28(5):871-7. PubMed ID: 18323514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Statin therapy--Part II: Clinical considerations for cardiovascular disease.
    Sadowitz B; Seymour K; Costanza MJ; Gahtan V
    Vasc Endovascular Surg; 2010 Aug; 44(6):421-33. PubMed ID: 20547576
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis.
    Bukkapatnam RN; Gabler NB; Lewis WR
    Prev Cardiol; 2010; 13(2):84-90. PubMed ID: 20377811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential role of statins in COVID-19.
    Lee KCH; Sewa DW; Phua GC
    Int J Infect Dis; 2020 Jul; 96():615-617. PubMed ID: 32502659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
    Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)".
    Jakob CEM; Borgmann S; Duygu F; Behrends U; Hower M; Merle U; Friedrichs A; Tometten L; Hanses F; Jung N; Rieg S; Wille K; Grüner B; Klinker H; Gersbacher-Runge N; Hellwig K; Eberwein L; Dolff S; Rauschning D; von Bergwelt-Baildon M; Lanznaster J; Strauß R; Trauth J; de With K; Ruethrich M; Lueck C; Nattermann J; Tscharntke L; Pilgram L; Fuhrmann S; Classen A; Stecher M; Schons M; Spinner C; Vehreschild JJ
    Infection; 2021 Feb; 49(1):63-73. PubMed ID: 33001409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elovanoids downregulate SARS-CoV-2 cell-entry, canonical mediators and enhance protective signaling in human alveolar cells.
    Calandria JM; Bhattacharjee S; Maness NJ; Kautzmann MI; Asatryan A; Gordon WC; Do KV; Jun B; Mukherjee PK; Petasis NA; Bazan NG
    Sci Rep; 2021 Jun; 11(1):12324. PubMed ID: 34112906
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
    Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
    MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statins and regression of coronary atherosclerosis.
    Athyros VG; Kakafika A; Karagiannis A; Mikhailidis DP
    JAMA; 2007 May; 297(20):2197; author reply 2197. PubMed ID: 17519408
    [No Abstract]   [Full Text] [Related]  

  • 51. Statins and coronary artery disease: clinical evidence and future perspective.
    Biasucci LM; Stefanelli A; Biasillo G
    Minerva Cardioangiol; 2012 Apr; 60(2):147-56. PubMed ID: 22495163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensive reduction of low-density lipoprotein-cholesterol: implications of recent trials.
    Hackam DG
    Am J Cardiovasc Drugs; 2006; 6(6):367-71. PubMed ID: 17192126
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.
    Orlowski S; Mourad JJ; Gallo A; Bruckert E
    Biochimie; 2021 Oct; 189():51-64. PubMed ID: 34153377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond statins: new lipid lowering strategies to reduce cardiovascular risk.
    Noto D; Cefalù AB; Averna MR
    Curr Atheroscler Rep; 2014 Jun; 16(6):414. PubMed ID: 24777633
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statins and Their Effect on PCSK9-Impact and Clinical Relevance.
    Taylor BA; Thompson PD
    Curr Atheroscler Rep; 2016 Aug; 18(8):46. PubMed ID: 27315084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of statins on atherosclerotic plaque.
    Almeida SO; Budoff M
    Trends Cardiovasc Med; 2019 Nov; 29(8):451-455. PubMed ID: 30642643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meta-analysis of Effect of Statins in Patients with COVID-19.
    Kow CS; Hasan SS
    Am J Cardiol; 2020 Nov; 134():153-155. PubMed ID: 32891399
    [No Abstract]   [Full Text] [Related]  

  • 58. All for Statins and Statins for All; An Update.
    Agouridis AP; Elisaf MS; Nair DR; Mikhailidis DP
    Curr Pharm Des; 2016; 22(1):18-27. PubMed ID: 26548311
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition.
    Musunuru K
    Annu Rev Med; 2021 Jan; 72():447-458. PubMed ID: 33234004
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.
    Jasińska M; Owczarek J; Orszulak-Michalak D
    Pharmacol Rep; 2007; 59(5):483-99. PubMed ID: 18048949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.